News
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...
After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...
NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...
Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...
AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback